These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 25048037)

  • 1. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs.
    Cao Y
    Nat Rev Endocrinol; 2014 Sep; 10(9):530-9. PubMed ID: 25048037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
    Tie J; Desai J
    Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
    Roodhart JM; Langenberg MH; Witteveen E; Voest EE
    Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy.
    Zhang Y; Yang Y; Hosaka K; Huang G; Zang J; Chen F; Zhang Y; Samani NJ; Cao Y
    Proc Natl Acad Sci U S A; 2016 Apr; 113(15):4158-63. PubMed ID: 27035988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF/VEGFR signalling as a target for inhibiting angiogenesis.
    Kiselyov A; Balakin KV; Tkachenko SE
    Expert Opin Investig Drugs; 2007 Jan; 16(1):83-107. PubMed ID: 17155856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.
    Yang Y; Zhang Y; Cao Z; Ji H; Yang X; Iwamoto H; Wahlberg E; Länne T; Sun B; Cao Y
    Proc Natl Acad Sci U S A; 2013 Jul; 110(29):12018-23. PubMed ID: 23818623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
    Launay-Vacher V; Deray G
    Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
    Takahashi S
    Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
    Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
    Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.
    Robinson ES; Khankin EV; Karumanchi SA; Humphreys BD
    Semin Nephrol; 2010 Nov; 30(6):591-601. PubMed ID: 21146124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor a inhibition in gastric cancer.
    Park DJ; Thomas NJ; Yoon C; Yoon SS
    Gastric Cancer; 2015 Jan; 18(1):33-42. PubMed ID: 24993497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy.
    Appelmann I; Liersch R; Kessler T; Mesters RM; Berdel WE
    Recent Results Cancer Res; 2010; 180():51-81. PubMed ID: 20033378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
    Epstein RJ
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The function of vascular endothelial growth factor.
    Nieves BJ; D'Amore PA; Bryan BA
    Biofactors; 2009; 35(4):332-7. PubMed ID: 19415738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor as a therapeutic target in cancer.
    Bergsland EK
    Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S4-11. PubMed ID: 15552621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs.
    Thanigaimani S; Kichenadasse G; Mangoni AA
    Curr Vasc Pharmacol; 2011 May; 9(3):358-80. PubMed ID: 20807189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
    Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
    Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.